Deals In Depth: September 2014
Merrimack licensed Baxter its Phase III pancreatic cancer candidate MM398 for $100 million up front and $620 million in pre-commercial milestones; Merck KGAA added life sciences products in its $16.7 billion acquisition of Sigma-Aldrich. Biopharma and device financing were both up from the previous month.
You may also be interested in...
A busy October will include planned biosimilar launches and key appointments for the off-patent sector.
Sandoz has had its say on its biosimilar rivals with largely branded portfolios, as well as the recent EMA statement supporting biosimilar interchangeability.
Delegates at the European Health Forum Gastein outlined the challenges facing an international effort to improve access to costly new medicines across the World Health Organization’s European region, insisting that the key issues had to be addressed “collectively” and without “finger pointing.”